ALTERITY THERAPEUTICS-ADR (ATHE) Fundamental Analysis & Valuation

NASDAQ:ATHE • US02155X2053

Current stock price

3.42 USD
-0.08 (-2.29%)
Last:

This ATHE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ATHE Profitability Analysis

1.1 Basic Checks

  • In the past year ATHE has reported negative net income.
  • In the past year ATHE has reported a negative cash flow from operations.
  • In the past 5 years ATHE always reported negative net income.
  • In the past 5 years ATHE always reported negative operating cash flow.
ATHE Yearly Net Income VS EBIT VS OCF VS FCFATHE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

  • ATHE has a better Return On Assets (-26.39%) than 68.92% of its industry peers.
  • Looking at the Return On Equity, with a value of -28.65%, ATHE is in the better half of the industry, outperforming 76.06% of the companies in the same industry.
Industry RankSector Rank
ROA -26.39%
ROE -28.65%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATHE Yearly ROA, ROE, ROICATHE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ATHE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHE Yearly Profit, Operating, Gross MarginsATHE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ATHE Health Analysis

2.1 Basic Checks

  • ATHE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for ATHE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATHE Yearly Shares OutstandingATHE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
ATHE Yearly Total Debt VS Total AssetsATHE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

  • An Altman-Z score of 8.28 indicates that ATHE is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ATHE (8.28) is better than 80.50% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that ATHE is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.00, ATHE is in line with its industry, outperforming 50.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.28
ROIC/WACCN/A
WACC9.38%
ATHE Yearly LT Debt VS Equity VS FCFATHE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M 30M

2.3 Liquidity

  • ATHE has a Current Ratio of 12.98. This indicates that ATHE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 12.98, ATHE belongs to the best of the industry, outperforming 87.45% of the companies in the same industry.
  • ATHE has a Quick Ratio of 12.98. This indicates that ATHE is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ATHE (12.98) is better than 87.45% of its industry peers.
Industry RankSector Rank
Current Ratio 12.98
Quick Ratio 12.98
ATHE Yearly Current Assets VS Current LiabilitesATHE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ATHE Growth Analysis

3.1 Past

  • ATHE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.62%, which is quite impressive.
  • ATHE shows a strong growth in Revenue. In the last year, the Revenue has grown by 66.28%.
  • The Revenue has been growing by 92.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)59.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.08%
Revenue 1Y (TTM)66.28%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%123.33%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
  • ATHE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 156.62% yearly.
EPS Next Y-7436.86%
EPS Next 2Y-768.15%
EPS Next 3Y-322.41%
EPS Next 5Y14.87%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y156.62%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ATHE Yearly Revenue VS EstimatesATHE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 200M 400M 600M 800M
ATHE Yearly EPS VS EstimatesATHE Yearly EPS VS EstimatesYearly EPS VS Estimates 2026 2027 2028 2029 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. ATHE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATHE. In the last year negative earnings were reported.
  • Also next year ATHE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHE Price Earnings VS Forward Price EarningsATHE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHE Per share dataATHE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • ATHE's earnings are expected to decrease with -322.41% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-768.15%
EPS Next 3Y-322.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATHE Dividend Analysis

5.1 Amount

  • ATHE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATHE Fundamentals: All Metrics, Ratios and Statistics

ALTERITY THERAPEUTICS-ADR

NASDAQ:ATHE (3/19/2026, 12:53:53 PM)

3.42

-0.08 (-2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)N/A
Inst Owners18.93%
Inst Owner Change-2.86%
Ins Owners1.91%
Ins Owner ChangeN/A
Market Cap61.99M
Revenue(TTM)446.30K
Net Income(TTM)-12.15M
Analysts80
Price Target3.37 (-1.46%)
Short Float %0.11%
Short Ratio1.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.09%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 196.93
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-30.14
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.02
BVpS1.65
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.39%
ROE -28.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.98
Quick Ratio 12.98
Altman-Z 8.28
F-Score5
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)15.55%
Cap/Sales(5y)732.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.08%
EPS Next Y-7436.86%
EPS Next 2Y-768.15%
EPS Next 3Y-322.41%
EPS Next 5Y14.87%
Revenue 1Y (TTM)66.28%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%123.33%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y156.62%
EBIT growth 1Y26.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-113.56%
EBIT Next 3Y-52.78%
EBIT Next 5Y37.28%
FCF growth 1Y9.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.16%
OCF growth 3YN/A
OCF growth 5YN/A

ALTERITY THERAPEUTICS-ADR / ATHE Fundamental Analysis FAQ

What is the fundamental rating for ATHE stock?

ChartMill assigns a fundamental rating of 4 / 10 to ATHE.


What is the valuation status of ALTERITY THERAPEUTICS-ADR (ATHE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALTERITY THERAPEUTICS-ADR (ATHE). This can be considered as Overvalued.


What is the profitability of ATHE stock?

ALTERITY THERAPEUTICS-ADR (ATHE) has a profitability rating of 1 / 10.


What is the expected EPS growth for ALTERITY THERAPEUTICS-ADR (ATHE) stock?

The Earnings per Share (EPS) of ALTERITY THERAPEUTICS-ADR (ATHE) is expected to decline by -7436.86% in the next year.